Argenx Se (ARGX) Cost of Revenue (2022 - 2026)
Argenx Se's (ARGX) quarterly Cost of Revenue came in at $145.0 million in Q2 2026, up 30.93% YoY from $110.7 million in Q2 2025, and up 19.83% on a QoQ basis from $121.0 million in Q1 2026.
Argenx Se (ARGX) Cost of Revenue (2022 - 2026) Analysis & Trends
Argenx Se (ARGX) has 5 years of Cost of Revenue data on file, last reported at $145.0 million in Q2 2026.
- Quarterly Cost of Revenue rose 30.93% year-over-year to $145.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $525.1 million (up 62.33% YoY) and the FY2025 annual result came in at $450.7 million, up 98.28% from the prior year.
- Cost of Revenue climbed to $145.0 million in Q2 2026, from $121.0 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $149.7 million in Q4 2025 to a low of $1.4 million in Q1 2022.
- A 5-year average of $60.6 million and a median of $47.8 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue jumped 1236.37% — and 2026, when it soared 30.93%.
- Tracing ARGX's Cost of Revenue over 5 years: stood at $12.8 million in 2022, then surged by 208.75% to $39.5 million in 2023, then jumped by 84.05% to $72.7 million in 2024, then soared by 106.02% to $149.7 million in 2025, then declined by 3.13% to $145.0 million in 2026.
- The last three Cost of Revenue figures came in at $145.0 million (Q2 2026), $121.0 million (Q1 2026), and $149.7 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 145.00 Mn |
| Jun 30, 2026 | 145.00 Mn |
| Mar 31, 2026 | 121.00 Mn |
| Mar 31, 2026 | 121.00 Mn |
| Dec 31, 2025 | 149.69 Mn |
| Dec 31, 2025 | 149.69 Mn |
| Sep 30, 2025 | 109.43 Mn |
| Sep 30, 2025 | 109.43 Mn |
| Jun 30, 2025 | 110.75 Mn |
| Jun 30, 2025 | 110.75 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Mar 31, 2025 | 81.00 Mn |
| Dec 31, 2024 | 72.66 Mn |
| Dec 31, 2024 | 72.66 Mn |
| Sep 30, 2024 | 59.07 Mn |
| Sep 30, 2024 | 59.07 Mn |
| Jun 30, 2024 | 52.38 Mn |
| Jun 30, 2024 | 52.38 Mn |
| Mar 31, 2024 | 43.18 Mn |
| Mar 31, 2024 | 43.18 Mn |